https://www.selleckchem.com/pr....oducts/oprozomib-onx
Although the literature recognizes the participation of patients in medical decisions as an important indicator of quality, there is a lack of consensus regarding the influence of advance directives (ADs) on reducing aggressive measures during end-of-life care involving cancer patients. A systematic review was conducted to analyze the influence of ADs on reducing aggressive end-of-life care measures for cancer patients. We searched the Medline, Embase, Web of Science, and Lilacs databases for studies published until March 201
Like
Comment
Share
